ACR20, ACR50 and ACR70 scores of up to 81%, 49% and 24% respectively at week 12 Very encouraging efficacy data compared to tocilizumab with up to 41% of patients in clinical remission at week 12 Favourable safety profile, based on initial data, at all administered doses Results from the 24 week Phase IIb study of vobarilizumab, as a combination therapy with methotrexate in RA, are expected later in Q3 2016 Conference call and webcast today at 4pm CET/10am ET GHENT, Belgium, July 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its anti-IL-6R Nanobody®, vobarilizumab (ALX-0061), successfully completed a 12 week treatment and assessment period...
↧